Gannet BioChem, a leading specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capital Partners, today announced the acquisition of Laysan Bio, a life sciences company based in Arab, Alabama. The acquisition strengthens Gannet BioChem’s capabilities across activated polymer technologies, including PEG reagents and bioconjugation while enhancing its ability to support partners from early development through GMP manufacturing.

Founded nearly two decades ago, Laysan Bio is a trusted supplier of cataloged, custom, and compliant activated polymer reagents to academic, biotechnology, and pharmaceutical organizations. The company’s technical expertise, quality systems, and program support capabilities complement Gannet BioChem’s growing platform and enhance its ability to serve a broad range of advanced therapeutic, drug delivery and now medical device programs.

“This acquisition meaningfully expands our technical depth and manufacturing flexibility across activated polymers and bioconjugation,” said Nicholas Shackley, CEO of Gannet BioChem. “Laysan Bio’s experience, talent, and customer relationships align closely with Gannet BioChem’s mission. Together, we are building a more comprehensive platform to support partners from discovery through commercial manufacturing.”

“Joining Gannet BioChem marks an exciting next chapter for our team and our customers,” said Jon McKannan, President of Laysan Bio. “This combination creates new opportunities to scale our capabilities, broaden our offerings, and further accelerate the programs we’ve helped advance over many years.”

The acquisition supports Gannet BioChem’s broader strategy to invest in specialized technologies and talent that enable innovation across activated polymers and bioconjugation, while maintaining a strong focus on quality, compliance, and long-term customer partnership.